Pesquisar
Liquidia Corp
LQDAAdicionar à lista de desejos
56.930USD
-2.370-4.00%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
5.06BValor de mercado
227.51P/L TTM
Mais detalhes de Liquidia Corp Empresa
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Informações de Liquidia Corp
Código da empresaLQDA
Nome da EmpresaLiquidia Corp
Data de listagemJul 26, 2018
CEOJeffs (Roger A)
Número de funcionários157
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 26
Endereço419 Davis Drive
CidadeMORRISVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27560
Telefone19193284400
Sitehttps://www.liquidia.com/
Código da empresaLQDA
Data de listagemJul 26, 2018
CEOJeffs (Roger A)
Executivos da empresa Liquidia Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-2.25%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
453.86K
+11.11%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
181.65K
+1.24%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
130.44K
-10.97%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
66.29K
-167.81%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
52.36K
+3.75%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
51.06K
-227.72%
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
20.36K
+9.64%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
15.36K
+12.78%
Dr. Stephen M. Bloch
Dr. Stephen M. Bloch
Independent Chairman of the board
Independent Chairman of the board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-2.25%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
453.86K
+11.11%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
181.65K
+1.24%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
130.44K
-10.97%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
66.29K
-167.81%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
52.36K
+3.75%
Detalhamento da receita
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
14.00M
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Farallon Capital Management, L.L.C.
9.73%
Caligan Partners, LP
9.13%
Manning (Paul B.)
6.18%
BlackRock Institutional Trust Company, N.A.
5.33%
Vanguard Capital Management, LLC
3.29%
Outro
66.34%
Investidores
Investidores
Proporção
Farallon Capital Management, L.L.C.
9.73%
Caligan Partners, LP
9.13%
Manning (Paul B.)
6.18%
BlackRock Institutional Trust Company, N.A.
5.33%
Vanguard Capital Management, LLC
3.29%
Outro
66.34%
Tipos de investidores
Investidores
Proporção
Hedge Fund
32.61%
Investment Advisor
20.58%
Investment Advisor/Hedge Fund
10.64%
Individual Investor
10.32%
Research Firm
3.41%
Corporation
2.58%
Family Office
2.01%
Private Equity
0.79%
Bank and Trust
0.48%
Outro
16.59%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
439
65.17M
73.52%
-6.80M
2025Q4
388
63.95M
73.51%
-2.03M
2025Q3
358
61.00M
70.12%
+1.28M
2025Q2
350
67.92M
79.46%
-5.32M
2025Q1
356
67.75M
79.47%
-4.91M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Farallon Capital Management, L.L.C.
8.66M
9.82%
+90.40K
+1.06%
Dec 31, 2025
Caligan Partners, LP
8.12M
9.21%
--
--
Dec 31, 2025
Manning (Paul B.)
6.22M
7.06%
+55.12K
+0.89%
Feb 11, 2026
BlackRock Institutional Trust Company, N.A.
4.74M
5.38%
+169.34K
+3.71%
Dec 31, 2025
Findell Capital Management LLC
2.85M
3.24%
+21.45K
+0.76%
Dec 31, 2025
Opaleye Management Inc.
2.44M
2.76%
-180.00K
-6.88%
Dec 31, 2025
Jeffs (Roger A)
2.23M
2.53%
+119.90K
+5.68%
Jan 16, 2026
Legend Aggregator LP
1.86M
2.11%
-5.32M
-74.10%
Dec 31, 2024
State Street Investment Management (US)
1.81M
2.05%
-105.00K
-5.49%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.68%
State Street SPDR S&P Pharmaceuticals ETF
2.33%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
1.07%
First Trust Small Cap Growth AlphaDEX Fund
0.83%
iShares U.S. Pharmaceuticals ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.41%
First Trust Small Cap Core Alphadex Fund
0.34%
iShares Micro-Cap ETF
0.3%
State Street SPDR S&P Kensho New Econ Comp ETF
0.27%
Ver Mais
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção2.68%
State Street SPDR S&P Pharmaceuticals ETF
Proporção2.33%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.07%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.83%
iShares U.S. Pharmaceuticals ETF
Proporção0.61%
Federated Hermes MDT Small Cap Core ETF
Proporção0.41%
First Trust Small Cap Core Alphadex Fund
Proporção0.34%
iShares Micro-Cap ETF
Proporção0.3%
State Street SPDR S&P Kensho New Econ Comp ETF
Proporção0.27%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
